Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
06086 方舟健客
FANGZHOU JIANKE
Listing Date2024/07/09
Listing Price8.180
 
Quote
  • 7.450 +0.090 (+1.223%)    Sink Below Listing Price
  • 15-min delayed, last update: 05/11/2024 17:59
Subscription Result
  • Subscription Rate
    16.63x
  • Guarantee One Lot Size
    4 lot
  • One Lot Success Rate
    40.04%
COMPANY PROFILE

Fangzhou Inc. commenced its business with a focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. Leveraging its chronic disease management platform, it is dedicated to providing tailored medical care and precision medicine for a growing population of chronic disease patients, with a view towards extending its services to a wider range of disease areas.

--

To address the needs of patients with chronic diseases for convenient and accessible medical care services, the Group provides comprehensive medical services and online retail pharmacy services through its Jianke Platform. In addition, a significant portion of its revenue was attributable to the sales of pharmaceutical and other healthcare products with service package.

--

The Group is the largest online chronic disease management platform in China in terms of average MAU in 2023, according to CIC. It ranked first in terms of prescription drug GMV in the online to-consumer CDM market in China.

--

Customers for the Group’s comprehensive medical services and online retail pharmacy services are mainly individual users. For its customized content and marketing solutions, its customers are mainly pharmaceutical companies.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
GLOBAL OFFERING
No. of Offer Shares23.80M shares
No. of International Offer Shares16.66M shares
No. of HK Offer Shares7.14M shares
Offer Price$7.60 - $8.36
Stock Code6086
Sponsor(s)Citigroup Global Markets Asia Limited, ABCI Capital Limited
Underwriter(s)Citigroup Global Markets Asia Limited, ABCI Securities Company Limited, Essence International Securities (Hong Kong) Limited, ICBC International Securities Limited, China Galaxy International Securities (Hong Kong) Co., Limited, China Everbright Securities (HK) Limited, China Merchants Securities (HK) Co., Limited, Citrus Securities Limited, CMB International Capital Limited, Fosun International Securities Limited, GF Securities (Hong Kong) Brokerage Limited, Huatai Financial Holdings (Hong Kong) Limited, Long Bridge HK Limited, Shenwan Hongyuan Securities (H.K.) Limited, Zhongtai International Securities Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Victory Securities Company Limited, Yue Xiu Securities Company Limited
TIME TABLE
Application PeriodJun 28 (Fri) - noon, Jul 04 (Thu)
Price Determination DateJul 05 (Fri)
Result Announcement DateOn or before Jul 08 (Mon)
Result Announcement DateOn or before Jul 08 (Mon)
Result Announcement DateOn or before Jul 09 (Tue)
Dealings in Shares commence onJul 09, 2024. (Tue)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$7.60 - $8.36
Capitalization10.19B - 11.20B
NAV / share ($)$0.11 - $0.12 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 7.98, the net proceeds raised would be HKD 63.07M, of which
67.4% : Used for business expansion in the next three to five years
16% : Used for research and development activities in the next five year
11.6% : Used for potential investments and acquisitions or strategic alliances with of the online chronic disease management industry
5% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
:
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.